Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson Sells 1,000 Shares of Stock

Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $230.00, for a total transaction of $230,000.00. Following the transaction, the director now directly owns 13,722 shares of the company’s stock, valued at $3,156,060. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Laboratory Co. of America Stock Down 0.6 %

NYSE:LH opened at $228.63 on Friday. The stock has a market cap of $19.20 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 1.70 and a beta of 1.05. The company has a current ratio of 0.88, a quick ratio of 0.77 and a debt-to-equity ratio of 0.39. The stock has a 50-day moving average price of $222.58 and a two-hundred day moving average price of $212.26. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $239.50.

Laboratory Co. of America (NYSE:LH) last released its earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.02. Laboratory Co. of America had a return on equity of 15.39% and a net margin of 3.60%. The business had revenue of $3.28 billion for the quarter, compared to the consensus estimate of $3.26 billion. During the same quarter in the previous year, the business earned $3.38 earnings per share. Laboratory Co. of America’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, equities analysts expect that Laboratory Co. of America Holdings will post 14.55 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Stockholders of record on Tuesday, November 26th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date is Tuesday, November 26th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 54.55%.

Institutional Investors Weigh In On Laboratory Co. of America

Several hedge funds have recently bought and sold shares of the company. Industrial Alliance Investment Management Inc. bought a new stake in Laboratory Co. of America in the 2nd quarter valued at $27,000. Horizon Bancorp Inc. IN acquired a new stake in shares of Laboratory Co. of America during the third quarter worth $29,000. Pathway Financial Advisers LLC bought a new stake in shares of Laboratory Co. of America in the first quarter valued at about $30,000. Innealta Capital LLC acquired a new position in shares of Laboratory Co. of America in the second quarter valued at about $32,000. Finally, Family Firm Inc. bought a new position in Laboratory Co. of America during the second quarter worth about $37,000. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group raised their price target on Laboratory Co. of America from $245.00 to $265.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Evercore ISI reduced their price target on shares of Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” rating on the stock in a research report on Tuesday, September 24th. Barclays upped their target price on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Laboratory Co. of America from $220.00 to $230.00 and gave the company a “hold” rating in a report on Friday, August 2nd. Finally, UBS Group lifted their target price on Laboratory Co. of America from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Laboratory Co. of America presently has a consensus rating of “Moderate Buy” and an average price target of $253.54.

About Laboratory Co. of America

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.